Profile: Daiichi Sankyo, Inc. concentrates on producing new therapies for cardiovascular disease, metabolic disorders, infection and cancer. Our evoxac® is FDA approved for the treatment of dry mouth symptoms in patients with Sjögren's syndrome. Our product welchol® is a cholesterol-lowering medication that works to lower LDL or bad cholesterol along with diet and exercise. It can be taken alone or with other cholesterol-lowering medications known as statins. Our marketed products include azor™, welchol®, evoxac®, benicar®, floxin® and evoxac®.